Skip to main content
. 2017 Jun 29;28(10):2985–2992. doi: 10.1681/ASN.2016121280

Figure 4.

Figure 4.

Differential expression of select miRNAs was validated in a second cohort of patients. (A) Abundance of miR-146a-5p and miR-24-3p in glomerular samples from additional patients with DN and FSGS on the basis of qPCR analysis. (B) Log2 fold differences of FSGS/DN from microRNA-sequencing analysis of original samples and qPCR analysis of new validation samples. *P<0.05; P=0.17 for miR-24-3p.